Neurology® Podcast

1) Muscular dystrophy and 2) Topic of the month: Aphasia. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Elliot Dimberg interviews Dr. Richard Finkel about his paper on muscular dystrophy. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week about anti-NMDA receptor antibody encephalitis. In the next part of the podcast Dr. Alberto Espay interviews Dr. Keith Josephs for the next part of our discussion on aphasias for our Lesson of the Week. Over the subsequent two weeks, we will continue to highlight the disorders of language. The participants had nothing to disclose except Drs. Dimberg, Finkel, Overman, Espay and Josephs. Dr. Dimberg serves as an editorial board member of AANEM Nerve and Muscle Junction Podcasts and as part of the Neurology® Podcast Panel, has received honoraria from ePocrates.com and Harris Interactive. Dr. Finkel serves on advisory boards for PTC Therapeutics, Inc., DuchenneConnect, Families of SMA, the National Fabry Disease Foundation, and TREAT-NMD; has received travel expenses for lectures not funded by industry; receives research support from PTC Therapeutics, Inc., Genzyme Corporation, Santhera Pharmaceuticals, the NIH (U54 AR0526446-03 [Co-I] and 1U54 NS0657-12-01 [Co-I]), the SMA Foundation, the Muscular Dystrophy Association, and the Foundation for the Eradication of Duchenne; and his spouse serves on the editorial board of Arthritis Research and Therapy, holds and has received license fees for numerous patents related to T cell activation and HIV, and receives research support from Merck Serono and the NIH in the field of T cell activation, HIV and genomics of juvenile arthritis.Dr. Overman serves as Deputy Editor on the Neurology® Resident and Fellow Section editorial team and the Neurology® Podcast Committee.Dr. Espay received has personal compensation as a consultant for Boehringer Ingelheim; grant support from Codman; Medtronic, Inc; Allergan, Inc.; and CleveMed, and honoraria from UCB-SCHWARZ PHARMA AG; Medtronic, Inc. and Novartis.Dr. Josephs is funded by R01- DC010367 (PI), the Dana Foundation (PI), and the Morris K. Udall PD Research Center of Excellence NIH/NINDS P50 NS40256 (Co-I).

1) Depression in Parkinson disease and 2) Topic of the month: Aphasia. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Russ Swerdlow interviews Dr. Massimo Filippi about his paper on depression in Parkinson disease. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week about five clues to the diagnosis of inclusion body myositis...and...amphiphysin antibody-associated stiff-person syndrome. In the next part of the podcast Dr. Alberto Espay interviews Dr. Keith Josephs about post-stroke aphasias for our Lesson of the Week. Over the next subsequent three weeks, we will highlight primary progressive aphasias. The participants had nothing to disclose except Drs. Filippi, Overman, Espay and Josephs. Dr. Filippi serves on scientific advisory boards for Teva Pharmaceutical Industries Ltd. and Genmab A/S; has received funding for travel from Bayer Schering Pharma, Biogen-Dompe AG, Genmab A/S, Merck-Serono, and Teva Pharmaceutical Industries Ltd.; serves on editorial boards of the American Journal of Neuroradiology, BMC Musculoskeletal Disorders, Clinical Neurology and Neurosurgery, Erciyes Medical Journal, Journal of Neuroimaging, Journal of Neurology Neurosurgery and Psychiatry, Journal of Neurovirology, Magnetic Resonance Imaging, Multiple Sclerosis, and Neurological Sciences; serves as a consultant to Bayer Schering Pharma, Biogen-Dompe AG, Genmab A/S, Merck-Serono, Pepgen Corporation, and Teva Pharmaceutical Industries Ltd.; serves on speakers' bureaus for Bayer Schering Pharma, Biogen-Dompe AG, Genmab A/S, Merck-Serono, and Teva Pharmaceutical Industries Ltd.; and receives research support from Bayer Schering Pharma, Biogen-Dompe AG, Genmab A/S, Merck-Serono, Teva Pharmaceutical Industries Ltd., Fondazione Italiana Sclerosi Multipla, and Fondazione Mariani. Dr. Overman serves as Deputy Editor on the Neurology® Resident and Fellow Section editorial team and the Neurology® Podcast Committee. Dr. Espay received has personal compensation as a consultant for Boehringer Ingelheim; grant support from Codman; Medtronic, Inc; Allergan, Inc.; and CleveMed, and honoraria from UCB-SCHWARZ PHARMA AG; Medtronic, Inc. and Novartis. Dr. Josephs is funded by R01- DC010367 (PI), the Dana Foundation (PI), and the Morris K. Udall PD Research Center of Excellence NIH/NINDS P50 NS40256 (Co-I).

1) Seasonal prevalence of MS and 2) New Clinical Practice Journal. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. John Scagnelli interviews Dr. Dominik Meier about his paper on MS disease activity. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week about drug-induced parkinsonism...and...alteplase-associated hemi?orolingual angioedema from the e-Pearl archives. In the next part of the podcast Dr. Ted Burns interviews Dr. John Corboy about the first issue of the new Clinical Practice Journal for our Lesson of the Week. The participants had nothing to disclose except Drs. Meier, Overman, Burns and Corboy. Dr. Meier has received research support from the NIH (R01 AG022092-01 [co investigator] and NCRR P41 RR013218 [consultant]. Dr. Overman serves as Deputy Editor on the Neurology® Resident and Fellow Section editorial team and the Neurology® Podcast Committee.Dr. Burns receives a stipend as Podcast Editor for Neurology®, and performs EMG studies in his neuromuscular practice (30% effort).Dr. Corboy serves as Editor for Clinical Practice Journal and Section Editor for Neurology Today, receives research support from Novartis [CFTY720D2309], the NIH [ NINDS1UO1NS4571901A1], and National MS Society and gave expert testimony in the trial of Colorado Anthony vs Loop, Morgan County District Court. A fixed 25 % of his salary is paid by the Rocky Mountain MS Center.

1) Cerebral artery infarctions 2) Antibiotics-cause of encephalopathy. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Justin Sattin interviews Dr. Adam Kelly about his paper on cerebral artery infarctions. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week about highlights from the e-Pearl archive. In the next part of the podcast Dr. Matthew Flaherty interviews Dr. Steven Lewis on antibiotics as a cause of encephalopathy for our Lesson of the Week. In concluding, there is a brief statement where to find other up-to date patient information and current Patient Page. The participants had nothing to disclose except Drs. Overman, Flaherty and Lewis.

1) Nonfluent primary progressive aphasia and 2) MuSK antibodies. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Farrah Mateen interviews Dr. Jonathan Rohrer about his paper on nonfluent primary progressive aphasia. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week about the Stransky sign. In the next part of the podcast Dr. Beau Bruce interviews Dr. Donald Sanders about MuSK antibodies for our Lesson of the Week. The participants had nothing to disclose except Drs. Rohrer, Mateen, Overman, Bruce and Sanders. Dr. Mateen has received grant funding from the AAN/AANF 2010 Practice Research Fellowship. Dr. Rohrer has received research support from the Wellcome Trust (Clinical Research Fellowship) and Brain (Exit Scholarship).Dr. Overman serves as Deputy Editor on the Neurology(R) Resident and Fellow Section editorial team and the Neurology(R) Podcast Committee.Dr. Bruce has received grant funding from the AAN/AANF Practice Research Fellowship and is funded by NIH grants UL1-RR025008 and KL2-RR025009.Dr. Sanders is a consultant for Accordant Health Services, Inc, Bayhill Therapeutics, Inc, Jacobus Pharmaceutical Co., Inc, BioMarin, Inc, Baxter International Inc., CytoKinetics, GlaxoSmithKline, and GTC Biotherapeutics, Inc, receives royalties from the publication of the book Single Fiber EMG and serves on the speakers' bureau of Athena Diagnostics and Talecris Biotherapeutics.

1) Comparative effectiveness research and 2) ACGME proposals for work duty hours. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Michael Benatar interviews Dr. Jacqueline French about her paper on comparative effectiveness research. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week about Guillain-Barré-like syndrome with thallium poisoning. In the next part of the podcast Dr. Ted Burns interviews Dr. Lori Schuh about ACGME recommendations for work duty hours for our Lesson of the Week. The participants had nothing to disclose except Drs. French, Overman, and Burns. Dr. French has served on scientific advisory boards for UCB, Johnson & Johnson, Eisai Inc., Novartis, Valeant Pharmaceuticals International, Icagen, Inc., Ikano Therapeutics Inc., Sepracor Inc., and Marinus Pharmaceuticals, Inc.; has received funding for travel from UCB, Kyowa Hakko Kirin Pharma, Inc., Eisai Inc., Johnson & Johnson, Valeant Pharmaceuticals International, and GlaxoSmithKline; serves as an Associate Editor of Epilepsy Currents and Supplement Editor for Epileptic Disorders; estimates that 30% of her time is spent in outpatient epilepsy practice; receives research support from the Epilepsy Therapy Development Project, FACES, Johnson & Johnson, Eisai Inc., UCB, SK Bio-Pharmaceuticals, Valeant Pharmaceuticals International, Vertex Pharmaceuticals, Pfizer Inc, Merck Serono, the NIH (R01 NS053998-01A1 [coinvestigator]), and from the Epilepsy Research Foundation; and serves as President of the Epilepsy Study Consortium, which receives money from multiple pharmaceutical companies. A fixed 20% of her NYU salary is paid by the study consortium, some of which may come from consulting fees from GlaxoSmithKline, Pfizer Inc, UCB, Johnson & Johnson, Cyberonics, Inc., SCHWARZ PHARMA, Ortho-McNeil-Janssen Pharmaceuticals, Inc., Eisai Inc., Jazz Pharmaceuticals, Ovation Pharmaceuticals, Endo Pharmaceuticals, Bial Pharmaceuticals, NeuroVista Corporation, Valeant Pharmaceuticals International, Icagen, Inc., Supernus Pharmaceuticals, Inc., Ikano Therapeutics Inc., SK Bio-Pharmaceuticals, TaroPharma, NeuroTherapeutics Pharma, Inc., Sepracor Inc., and Novartis. Dr. Overman serves as Deputy Editor on the Neurology® Resident and Fellow Section editorial team and the Neurology® Podcast Committee.Dr. Burns receives a stipend as Podcast Editor for Neurology®, and performs EMG studies in his neuromuscular practice (30% effort).

1) Acute progressive neurologic decline and absence of mass lesion and 2) AAN.com and community features it provides. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Karen Roos interviews Drs. Jason Taub and Jeffrey Olson about their paper on acute progressive neurologic decline. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week about unilateral photophobia or phonophobia in cluster headache. In the next part of the podcast Dr. Ted Burns interviews Dr. Daniel Hoch and Jose Merino about AAN.com and the community features it provides for our Lesson of the Week. The participants had nothing to disclose except Drs. Roos, Olson, Overman, Burns, Hoch, and Jose Merino. Dr. Roos serves as Editor-in-Chief of Seminars in Neurology, received royalties for 4 published textbooks, received funding for traveling from the AAN and other universities, and gave expert testimony, but monies received were forwarded to the Department of Neurology, Indiana University School of Medicine.Dr. Olson serves on the Data Safety Monitoring Board for Monteris, Inc., and has funded clinical research for which he is the Emory PI by Wyeth, Myriad Genetics, Inc., and Baxter International Inc.; and receives research support from the NIH (UO1CA137433-01 [Site PI], R01 CA116174 [Co-I], R01 CA121320-01 [Co-I], and R21 CA141836 [PI]).Dr. Overman serves as Deputy Editor on the Neurology® Resident and Fellow Section editorial team and the Neurology® Podcast Committee.Dr. Burns receives a stipend as Podcast Editor for Neurology®, and performs EMG studies in his neuromuscular practice (30% effort).Dr. Hoch serves as an editorial board member of AAN.com, holds stock options in Merck Serono and Biogen Idec, and gave expert testimony in the trial for the State of Massachusetts, Essex County, 2008-2010.Jose Merino receives a stipend as Associate Editor for AAN.com, serves as an editorial board member of Stroke and receives salary support from NINDS contract with Suburban Hospital.

1) Multiple sclerosis: A meta-analytic approach 2) Ultrasound of peripheral nerves (Part 2). This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Mark Keegan interviews Dr. Maria Pia Sormani about her paper on multiple sclerosis: A meta-analytic approach. In the next segment, Dr. Jennifer Fugate is reading our e-Pearl of the week about Terson syndrome. In the next part of the podcast Dr. Mary Lussier interviews Dr. Michael Cartwright for part two on peripheral nerve ultrasound for our Lesson of the Week. In concluding, there is a brief statement where to find other up-to date patient information and current Patient Page. The participants had nothing to disclose except Drs. Sormani, Keegan, Fugate, and Cartwright.

1) Mild cognitive decline 2) Ultrasound of peripheral nerves (Part 1). This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jeff Burns interviews Dr. Susan Landau about her paper on mild cognitive decline. In the next segment, Dr. Jennifer Fugate is reading our e-Pearl of the week about Doi's sign. In the next part of the podcast Dr. Mary Lussier interviews Dr. Michael Cartwright for part one on peripheral nerve ultrasound for our Lesson of the Week. The participants had nothing to disclose except Drs. Landau, Fugate, and Cartwright. Dr. Landau receives research support from the NIH (U01 AG024904 [Research specialist]).Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Cartwright receives research support from the NIH (1K23 N5062892-01A1) and has received speaker honoraria from AANEM and ASN annual meetings.

In this special podcast for the Neurology Journal, Dr. Ted M. Burns plays a dozen of the many interesting audio clips from Neurology Podcasts of the 2009-2010 academic year.

1) Diagnosis of acute ischemic stroke and 2) evidence-based medicine (Part 3). This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Brett Kissela interviews Dr. Peter Schellinger about his paper on diagnosis of acute ischemic stroke. In the next segment, Dr. Jennifer Fugate is reading our e-Pearl of the week about digiti quinti sign. In the next part of the podcast Dr. Michael Benatar interviews Dr. Mark Conaway for part three on evidence-based medicine probability, odds, and odds ratio for our Lesson of the Week. The participants had nothing to disclose except Drs. Kissela, Schellinger and Fugate. Dr. Kissela served on the scientific advisory board for Allergan, Inc in 2009; served as a consultant for Allergan for 2-day meeting in 2009; received honoraria from CME program and unrestricted educational grants; received research support from the NIH [R01 NS 30678], [N01 NS 081588], [1Ul1 RR026314] and received compensation for reviewing records for several medical/legal cases regarding stroke.Dr. Schellinger has served/serves on scientific advisory boards for Boehringer Ingelheim, ImaRx Therapeutics, Photothera, Cerevast, and CoAxia, Inc.; has served/serves on speakers' bureaus for and received funding for travel and speaker honoraria from Boehringer Ingelheim, Sanofi, ImaRx Therapeutics, Photothera, Cerevast, CoAxia, Inc., Solvay Pharmaceuticals, Inc., and GlaxoSmithKline; serves on editorial boards of Stroke and European Neurology; receives royalties from the publication of NeuroIntensiv (Springer, 2008) and received royalties from the publication of Stroke MRI (Steinkopff, 2004); has served as a consultant for CoAxia, Inc., Photothera, Cerevast, ImaRx, and Boehringer Ingelheim; and has provided expert testimony, affidavits, and acted as a witness or consultant in legal proceedings.Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section.

1) Depressive symptoms and risk of dementia and 2) Early history of the AAN. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. David Geldmacher interviews Dr. Jane Saczynski about her paper on depressive symptoms and risk of dementia. In the next segment, Dr. Jennifer Fugate is reading our e-Pearl of the week about wrong way eyes. In the next part of the podcast Dr. Ted Burns interviews Dr. Robert Joynt on the early history of the AAN for our Lesson of the Week. The participants had nothing to disclose except Drs. Fugate, Burns and Joynt. Dr. Geldmacher serves on editorial board of Brain Injury, has received speaker honoraria from Danville Regional Medical Center, Georgetown Medical School, University of Rochester, Cleveland Clinic, Kaiser Permanante and Academy for Healthcare Education, receives research support from Elan Corporation [PI], Eisai Inc. [PI], Medivation, Inc. [PI], Janssen [PI] and Novartis [PI].Dr. Fugate serves on the editorial team for the Neurology® Resident and Fellow Section. Dr. Burns receives a stipend as Podcast Editor for Neurology®, and performs EMG studies in his neuromuscular practice (30% effort).Dr. Joynt receives a stipend as Newsletter Editor for Neurology® and royalties from Archives of Neurology for published work.

1) Imaging in acute stroke and 2) conflicts of interest: A personal perspective. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Brett Kissela interviews Dr. Yves Samson about his paper on diffusion-weighted MR imaging in acute stroke. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week about posterior vermal split syndrome. In the next part of the podcast Dr. Matthew Wong interviews Dr. Joseph Martin for our Lesson of the Week about his paper on the pervasive influence of conflicts of interest. The participants had nothing to disclose except Drs. Kissela, Samson and Martin. Dr. Kissela served on the scientific advisory board for Allergan, Inc in 2009; served as a consultant for Allergan for 2-day meeting in 2009; received honoraria from CME program and unrestricted educational grants; received research support from the NIH [R01 NS 30678], [N01 NS 081588], [1Ul1 RR026314] and received compensation for reviewing records for several medical/legal cases regarding stroke. Dr. Samson is co-inventor of Neurinfarct software (Patent WO 2008/000973, issued 2008) currently owned by Intelligence in Medical Technologies, Paris; and holds stock in Intelligence in Medical Technologies. Dr. Martin has been on the Board of Directors at Baxter International for 8 years. For a short narrative describing this activity in greater detail, and the effect it had on Dr. Martin's activities, please see appendix e-1 at www.neurology.org

1) Restless legs syndrome and 2) evidence-based medicine (part 2). This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Aman Savani interviews Dr. Diego Garcia-Borreguero about his paper on restless legs syndrome. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week about fatal gastroenteritis. In the next part of the podcast Dr. Michael Benatar interviews Dr. Mark Conaway for part two on evidence-based medicine relative risk, relative risk reduction, absolute risk reduction, and NNT for our Lesson of the Week. You may also want to check out the other two-part series on evidence-based medicine where Dr. Michael Benatar interviewed Dr. Gary Gronseth for our March 30 and April 6 Lesson of the Week. The participants had nothing to disclose except Dr. Garcia-Borreguero. Dr. Garcia-Borreguero has served on scientific advisory boards for and received speaker honoraria from Boehringer Ingelheim, GlaxoSmithKline, UCB, Pfizer Inc, XenoPort, Inc., sanofi-aventis, Jazz Pharmaceuticals, and Merck & Co., Inc.

1) Embouchure dystonia and 2) progressive myoclonic encephalopathies. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Robert Pascuzzi interviews Dr. Bernhard Haslinger about his paper on embouchure dystonia. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week about the corneal reflex in stroke. In the next part of the podcast Dr. Alberto Espay interviews Dr. Berge Minassian for part 2 on progressive myoclonic encephalopathies for our Lesson of the Week. The participants had nothing to disclose except Drs. Haslinger, Pascuzzi and Espay. Dr. Haslinger serves on a scientific board for Merz Pharmaceuticals, LLC; has received funding from travel from Ipsen, Merz Pharmaceuticals, LLC, and Medtronic, Inc.; has received speaker honoraria from Novartis, GlaxoSmithKline, Desitin Pharmaceuticals, GmbH, Ipsen, and Allergan, Inc.; receives research support from Ipsen and from the German Research Foundation (DFG).Dr. Pascuzzi serves on the Board of Directors of the ABPN; serves on the Neurology RRC; served as immediate past Program Director for Neurology Residency Training at Indiana University; participates in multicenter clinical trials for a variety of neuromuscular disorders but receives no direct compensation; and gives lectures for the AAN and at multiple academic medical centers but does not received personal compensation.Dr. Espay received has personal compensation as a consultant for Boehringer Ingelheim; grant support from Codman; Medtronic, Inc; Allergan, Inc.; and CleveMed, and honoraria from UCB-SCHWARZ PHARMA AG; Medtronic, Inc. and Novartis.

1) Guillain-Barré syndrome vs. CIDP and 2) progressive myoclonic encephalopathies. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Erik Ensrud interviews Dr. Pieter van Doorn about his paper on Guillain-Barré syndrome. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week about Harlequin syndrome. In the next part of the podcast Dr. Alberto Espay interviews Dr. Berge Minassian for part 1 on progressive myoclonic encephalopathies for our Lesson of the Week. The participants had nothing to disclose except Drs. van Doorn and Espay.Dr. van Doorn receives research support from the Prinses Beatrix Fonds, the GBS-CIDP Foundation International and from Baxter biopharmaceutics.Dr. Espay received has personal compensation as a consultant for Boehringer Ingelheim; grant support from Codman; Medtronic, Inc; Allergan, Inc.; and CleveMed, and honoraria from UCB-SCHWARZ PHARMA AG; Medtronic, Inc. and Novartis.

Frontotemporal dementia and advocacy. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jeff Burns interviews Dr. Eneida Mioshi about her paper on frontotemporal dementia. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week about atypical unilateral severe facial pain in smokers. In the next part of the podcast Dr. Ted Burns interviews Dr. Robert Griggs on advocacy for our Lesson of the Week. The participants had nothing to disclose except Drs. Mioshi, Burns and Griggs.Dr. Mioshi serves on the editorial board of Dementia and Geriatric Cognitive DisordersDr. Burns receives a stipend as Podcast Editor for Neurology®, and performs EMG studies in his neuromuscular practice (30% effort).Dr. Griggs serves on the editorial advisory board for Current Treatment Options in Neurology and NeuroRX; has received honoraria for lectures or educational activities not funded by industry; receives research support from the NINDS T32 NS07338 [PI]; NIH 2U54 NS059065-06 [PI], R01 NS045686-05 [PI], NIH-R13 Fostering Pharma, NINDS 525326 FOR-DMD, and FDA 2-RO1FD003454-02 [Co-PI] and TaroPharma; receives funding support from MDA Fostering Pharma-Academic Partnerships in Neuromuscular Experimental Therapeutics, Muscular Dystrophy Association Experimental Therapeutics of Neuromuscular Disease and Recruitment for HYP HOP Phase III trial in the Periodic paralyses (PI); and receives royalties from the publication of the book, Cecil Textbook of Medicine, 23 Edition.

Hippocampal removal and evidence-based medicine (part 1). This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ryan Overman interviews Dr. Marla Hamberger about her paper on hippocampal removal. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week about the "slurp" test for children with myasthenia gravis. In the next part of the podcast Dr. Michael Benatar interviews Dr. Mark Conaway for part one on evidence-based medicine risk and rate for our Lesson of the Week. The participants had nothing to disclose except Drs. Overman and Hamberger. Dr. Overman serves as Deputy Editor on the Neurology® Resident and Fellow Section editorial team and the Neurology® Podcast Committee. Dr. Hamberger serves on the editorial board of Epilepsy and Behavior and receives research support from the NIH (NINDS R01 NS35140 [PI]). Dr. Overman serves as Deputy Editor on the Neurology® Resident and Fellow Section editorial team and the Neurology® Podcast Committee.Dr. Hamberger serves on the editorial board of Epilepsy and Behavior and receives research support from the NIH (NINDS R01 NS35140 [PI]).

Leptomeningeal metastases and acute dizziness. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Michelle Mauermann interviews Dr. Lisa DeAngelis about her paper on leptomeningeal metastases. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week about hemiballism. In the next part of the podcast Dr. Beau Bruce interviews Dr. David Newman-Toker on acute dizziness for our Lesson of the Week. The participants had nothing to disclose except Dr. DeAngelis.Dr. DeAngelis has served on a scientific advisory board for Genentech, Inc.; serves on the editorial board of Neurology; receives royalties from the publication of The Neurologic Complications of Cancer (Oxford University Press, 2008); and has received research support from the NIH (UO1 CA-105663-01 [Participating Member in the NABTC]).

Safety of t-PA in stroke and Rett syndrome. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Andy Southerland interviews Dr. Sean Savitz about his paper on safety of t-PA in stroke. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week about ophthalmoplegia in herpes zoster ophthalmicus. In the next part of the podcast Dr. Alberto Espay interviews Dr. SakkuBai Naidu for our Lesson of the Week about Rett syndrome. In concluding, there is a brief statement where to find other up-to date patient information and current Patient Page. The participants had nothing to disclose except Drs. Savitz and Espay. Dr. Savitz serves on a scientific advisory board for Grupo Ferrer Internacional S.A.; has received travel expenses and/or honoraria for lectures or educational activities not funded by industry; serves as an Associate Editor of Experimental and Translational Stroke Medicine; has received honoraria from Johnson & Johnson; receives research support from Athersys, the NIH R21NS064316 [PI] and R21 HD060978 [PI], the American Heart Association, and from the Howard Hughes Medical Institute.Dr. Espay received has personal compensation as a consultant for Boehringer Ingelheim; grant support from Codman; Medtronic, Inc; Allergan, Inc.; and CleveMed, and honoraria from UCB-SCHWARZ PHARMA AG; Medtronic, Inc. and Novartis.

Driving risk in dementia and survey results on sedation for imminently dying. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Russ Swerdlow interviews Dr. Don Iverson about the AAN guidelines update on driving risk in dementia. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week about motor movements in brain death. In the next part of the podcast Dr. Ted Burns interviews Dr. Jim Russell for our Lesson of the Week about the AAN Ethics Section survey results on sedation for the imminently dying. The participants had nothing to disclose except Drs. Burns and Russell.Dr. Burns receives a stipend as Podcast Editor for Neurology®, and performs EMG studies in his neuromuscular practice (30% effort).Dr. Russell serves on the scientific advisory board for the Massachusetts Chapter of the ALS Association; and receives royalties from the publication of Neuromuscular Disorders (McGraw-Hill, 2007).

Migraine care and principles of bioethics (part 3). This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jim Gordon interviews Dr. Rachel Nardin about her paper on migraine care in the United States. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week about stroke with primary brain tumors. In the next part of the podcast, Dr. Ted Burns interviews Dr Dan Larriviere for our Lesson of the week about principles of bioethics: respect of nonmaleficence. The participants had nothing to disclose except Drs. Gordon, Nardin, Burns and Larriviere.Dr. Gordon has received speaker fees from the University of Washington School of Nursing for two talks.Dr. Nardin has received honoraria for lectures not funded by industry; serves on the editorial board of Muscle & Nerve; and has received royalties from publications in Up-to-date.Dr. Burns receives a stipend as Podcast Editor for Neurology®, and performs EMG studies in his neuromuscular practice (30% effort).Dr. Larriviere has received honoraria for serving on the American Association for the Advancement of Science Faculty and has received an unrestricted educational grant from Allergan, Inc.

Poliovirus-infected macrophages in thymus and part two on evidence-based medicine. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Renato Bernasconi about his paper on myasthenia gravis. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week about a mimic of hemicranias continua. In the next part of the podcast Dr. Michael Benatar interviews Dr. Gary Gronseth for part two on evidence-based medicine for our Lesson of the Week. The participants had nothing to disclose except Drs. Burns and Gronseth.Dr. Burns receives a stipend as Podcast Editor for Neurology®, and performs EMG studies in his neuromuscular practice (30% effort).Dr. Gronseth serves as an editorial advisory board member of Neurology Now; serves on a speakers bureau for Boehringer Ingelheim; and receives honoraria from Boehringer Ingelheim and the American Academy of Neurology.

Subdiaphragmatic visceral infarction and part one on evidence-based medicine. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Justin Sattin interviews Dr. Pierre Amarenco about his paper on visceral infarction in cardioembolic stroke. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week about neuroimaging in paroxysmal hemicranias and SSUNCT syndrome. In the next part of the podcast Dr. Michael Benatar interviews Dr. Gary Gronseth for part one on evidence-based medicine for our Lesson of the Week. The participants had nothing to disclose except Dr. Gronseth.Dr. Gronseth serves as an editorial advisory board member of Neurology Now; serves on a speakers bureau for Boehringer Ingelheim; and receives honoraria from Boehringer Ingelheim and the American Academy of Neurology.

Familial essential tremor and update H1N1 and risk of GBS. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Matt Barrett interviews Dr. Giuseppe Nicoletti about his paper on familial essential tremor. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week about fibrocartilaginous embolism myelopathy. In the next part of the podcast Dr. Ted Burns interviews Dr. Jim Sejvar for our Lesson of the Week about H1N1 vaccination and risk of GBS an update. The participants had nothing to disclose except Dr. Burns.Dr. Burns receives a stipend as Podcast Editor for Neurology®, and performs EMG studies in his neuromuscular practice (30% effort).

Non-motor symptoms of Parkinson disease and improving the no-show rate in residents clinic. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jeremy Lanford interviews Dr. Theresa Zesiewicz about the AAN guidelines on non-motor symptoms of Parkinson disease. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week. In the next part of the podcast Dr. Alex Menze interviews Dr. Raymond Price for our Lesson of the Week about Resident & Fellow submission on education research. The participants had nothing to disclose except Dr. Zesiewicz.Dr. Zesiewicz has received funding for travel from and served on speakers bureaus for Boehringer Ingelheim and Teva Pharmaceutical Industries Ltd.; and receives research support from Boehringer Ingelheim, Novartis, GlaxoSmithKline, UCLA-RAND, Teva Neuroscience, Pfizer Inc, Allergan, Inc., the National Ataxia Foundation, Friedreich's Ataxia Research Association, and from the Bill Allison Ataxia Research Center.

Fibrillar amyloid-beta and Bioethics-beneficence. This podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Brandy Matthews interviews Dr. Susan Resnick about her paper on cognitive decline is associated with fibrillar amyloid-beta. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week about the Eastchester clapping sign. In the next part of the podcast Dr. Ted Burns interviews Dr. Dan Larriviere for our Lesson of the Week about principles of bioethics-beneficence. The participants had nothing to disclose except Drs. Resnick, Matthews, Larriviere, and Burns.Dr. Resnick serves as Action Editor for Brain and Cognition; and received research support from the NIH/NIA Intramural Research Program.Dr. Matthews received honoraria for attending the AAN Annual Meeting in Seattle in 2009; and received research support from Indiana Alzheimer Disease Center, and NIA funded program from 2008 to present.Dr. Larriviere has received honoraria for serving on the American Association for the Advancement of Science Faculty; and has received an unrestricted educational grant from Allergan, Inc.Dr. Burns receives a stipend as Podcast Editor for Neurology®; and performs EMG studies in his neuromuscular practice (30% effort).

This Podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Andrea Pace about his paper on cisplatin neuropathy. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week about atrophy in MuSK-antibody positive myasthenia gravis. In the next part of the podcast Dr. Alberto Espay interviews Dr. Joanna Jen for our Lesson of the Week about benign paroxysmal positional vertigo vs. posterior circulation stroke. The participants had nothing to disclose except Drs. Pace, Burns and Espay. Dr. Pace has received speaker honoraria from Schering-Plough Corp. and Italfarmaco.Dr. Burns receives a stipend as Podcast Editor for Neurology®, and performs EMG studies in his neuromuscular practice (30% effort).Dr. Espay received has personal compensation as a consultant for Boehringer Ingelheim; grant support from Codman; Medtronic, Inc; Allergan, Inc.; and CleveMed, and honoraria from UCB-SCHWARZ PHARMA AG; Medtronic, Inc. and Novartis.

This Podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Hans Dieter Katzberg about the AAN guidelines on treatment for muscle cramps. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week about coat hanger sing in multiple sclerosis atrophy. In the next part of the podcast Dr. Beau Bruce interviews Dr. Robert Naismith for our Lesson of the Week about natalizumab (Tysabri). The participants had nothing to disclose except Drs. Burns and Katzberg. Dr. Burns receives a stipend as Podcast Editor for Neurology®, performs EMG studies in his neuromuscular practice (30% effort), and received compensation for a presentation on MG-QOL15, given to study investigators of eculizumab in myasthenia gravis.Dr. Katzberg has received funding for travel from the Muscular Dystrophy Association.

This Podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Benjamin Atkinson interviews Dr. Thanh Phan about his paper on hypoxic coma: A meta-analysis. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week about distinguishing dystonic tremor from essential tremor. In the next part of the podcast Dr. Julian Bragg interviews Dr. Miguel Hernán for our Lesson of the Week about bias. The participants had nothing to disclosure.

This Podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Brett Kissela interviews Dr. John Ly about his paper on cerebral amyloid angiopathy related hemorrhage. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week about psychogenic non-epileptic seizures. In the next part of the podcast, Dr. Ted Burns interviews Dr Dan Larriviere for our Lesson of the week toolbox about principles of bioethics: respect of autonomy. The participants had nothing to disclosure except for Drs. Kissela, Larriviere and Burns.Dr. Kissela served on the scientific advisory board for Allergan, Inc in 2009; served as a consultant for Allergan for 2-day meeting in 2009; received honoraria from CME program and unrestricted educational grants; received research support from the NIH [R01 NS 30678], [N01 NS 081588], [1Ul1 RR026314] and received compensation for reviewing records for several medical/legal cases regarding stroke.Dr. Burns receives a stipend as Podcast Editor for Neurology®, performs EMG studies in his neuromuscular practice (30% effort), and received compensation for a presentation on MG-QOL15, given to study investigators of eculizumab in myasthenia gravis.Dr. Larriviere has received honoraria for serving on the American Association for the Advancement of Science Faculty and has received an unrestricted educational grant from Allergan, Inc.

This Podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Mark Quigg interviews Dr. Rainer Surges and Prof. Matthew Walker about their paper on generalized seizures. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week about HSV-1 encephalitis and falsely negative PCR. In the next part of the podcast is Dr. Alberto Espay interviews Dr. Curt LaFrance for our Lesson of the week toolbox about psychogenic non-epileptic seizures. The participants had nothing to disclosure except for Prof. Walker, Drs. Surges and Espay. Dr. Surges received research support from Deutsche Forschungsgemeinschaft.Prof. Walker serves on scientific advisory boards for GlaxoSmithKline, Eisai Inc., UCB, and Sierra Neuro; has received travel expenses and honoraria for lectures or educational activities not funded by industry; serves as an Associate Editor of Epilepsia and Therapeutic Advances in Neurological Disorders and on the editorial boards of The Open Neurology Journal, Expert Opinion on Emerging Drugs, and Metabolic Brain Disease; receives royalties from publishing Understanding Epilepsy (BMA Family Doctor books, 1995); has received speaker honoraria from Eisai Inc. and UCB; serves as a consultant to Sierra Neuro; estimates that 20% of his clinical effort is on Video-EEG telemetry; and has received/receives research support from the Medical Research Council [G0400136 (PI), G0802158 (Co-I), G0701050 (Co-I), and G069336 (Co-I)], the European Community, Wellcome Trust, and Epilepsy Research UK.Dr. Espay has received personal compensation as a consultant for Boehringer Ingelheim; grant support from Codman; Medtronic, Inc; Allergan, Inc.; and CleveMed, and honoraria from UCB-SCHWARZ PHARMA AG; Medtronic, Inc. and Novartis.

1. Brain death, the determination of brain death, and member guidance for brain death accommodation requests: AAN position statement. 2. [What's Trending]: On tau protein and Alzheimer dementia symptoms. In the first segment, Dr. Jason Crowell talks with Dr. James Russell about his paper on brain death, the determination of brain death, and member guidance for brain death accommodation requests. In the second part of the podcast, Dr. Jeff Burns focuses his interview with Dr. Matthew Brier on tau protein and Alzheimer dementia symptoms.DISCLOSURES: Dr. Jason Crowell reports no disclosures. Dr. James Russell has served on Scientific Advisory Boards for Cytokinetics - Data Monitoring Board PROTOCOL CY 5022 A PHASE 2, MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, DOSE- RANGING, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF CK-2127107 IN PATIENTS WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS). Dr. James Russell received travel funding from 1) Non-profit - Mexican Academy of Neurology - Funded travel and lodging to speak at Annual Meeting Nov 2018 - no honorarium (2) Non-profit - ALS Association - funded travel and lodging to do site visit for ALSA certification of UVA ALS Clinic. Dr. James Russell has publishing royalties from (1) Neuromuscular Disorders, McGraw-Hill, 2nd edition published 2015, with subsequent royalities 2) Honorarium for published article in Continuum: Approach to peripheral neuropathy. Continuum: Peripheral Nervous System Disorders. Fall 2017. Dr. James Russell has done consultancies with compensation for market research interviews regarding ALS therapeutics and is currently being compensated for expert opinion in two medical legal cases, one in support of the defendant and one in support of the plaintiff. Dr. Matthew Brier has received funding for Biogen, travel and accommodation and received research support for Medical Scientist Training Program Grant to WUSTL (5T32GM007200-37.

This Podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Shanna Patterson interviews Dr. Mauricio Delgado about his AAN guidelines on children and adolescents with cerebral palsy. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week about triple-H sign in anterior choroidal artery infarction. The next part of the podcast is Dr. Alberto Espay interviews Dr. Joanna Jen for our Lesson of the week toolbox about benign paroxysmal positional vertigo vs. posterior circulation stroke. The participants had nothing to disclosure except Drs. Delgado and Espay. Dr. Delgado serves on the editorial board of Developmental Medicine and Child Neurology; has received research support from Abbott, Sciele Pharma, Inc., UCB, Allergan, Inc., the Hurst Foundation, the United Cerebral Palsy Research & Educational Foundation, the Linda and Don Carter Foundation, and the Crowley Carter Foundation; and estimates 50% of his clinical effort is spent on assessment and management of motor disorders of childhood, which includes treating children with cerebral palsy with oral antispasticity medications, ITB, and botulinum toxin injections.Dr. Espay has received personal compensation as a consultant for Boehringer Ingelheim; grant support from Codman; Medtronic, Inc; Allergan, Inc.; and CleveMed, and honoraria from UCB-SCHWARZ PHARMA AG; Medtronic, Inc. and Novartis.

This Podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Valerie Voon about her paper on conversion disorder. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week about checklist for using intravenous phenytoin. The next part of the podcast is the second portion to an interview by Dr. Beau Bruce talking with Dr. Stewart Teppert about triptans. The participants had nothing to disclosure except Dr. Voon. Dr. Voon serves on a scientific advisory board for Boehringer Ingelheim; serves on the editorial board of Movement Disorders; and was supported by an intramural National Institute of Neurological Disorders and Stroke fellowship.

This Podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interviews Dr. Richard Dubinsky about his paper on transcutaneous electric nerve stimulation. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week about neuroacanthocytosis can mimic Huntington disease. The next part of the podcast is excerpts from an AANEM interview with Dr. Ray Adams along with a brief introduction from Dr. Ted Burns. Theres a book review about Dr. Ray Adams in this weeks issue of Neurology. Please be sure to check out the review of the book, which is titled: Raymond Adams. A life of mind and muscle by Dr. Peter J. Koehler. The participants had nothing to disclosure except Dr. Dubinsky. Dr. Dubinsky serves on a scientific advisory board and speakers bureau for Allergan, Inc.; receives honoraria from BrioMed; receives research support from Allergan, Inc., Merz Pharmaceuticals GmbH, and the NIH [NHGRI/NINDS #1R01HG02449-01 (Site Investigator); NIAM/NINDS #R01NS052592 (Site Investigator), NIAM/NINDS #R01NS052619-01 (Site Investigator), NIAM/NINDS #R01NS052592-01 (Site Investigator), NCCAM #2007P000827 (Site Investigator), NCCAM #UO1AT000613 (Site Investigator)]; and his spouse owns stock in Abbott.

This Podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Juliana Lockman interview Dr. Roderick Duncan about his paper on psychogenic non epileptic attacks. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week about rosary-like calcifications in carotid stenosis. The next part of the podcast is Dr. Michael Benatar interviews Dr. Chris Coffey for our Lesson of the week about non-inferiority trials. In concluding, there is a brief statement where to find other up-to date patient information and current Patient Page. The participants had nothing to disclosure except Dr. Duncan. Dr. Duncan has received speaker honoraria and funding for travel from UCB.

This Podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Jeff Burns interview Dr. Stephen Salloway about his paper on using bapineuzumab in mild to moderate Alzheimer disease. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week about the Heidenhain variant of Creutzfeldt Jakob disease. The podcast concludes where Dr. Beau Bruce interviews Dr. Brian Weinshenker for the Lesson of the Week (disease of the month) on triptans. The participants had nothing to disclose except Drs. Burns & Salloway. Dr. Burns serves on the Neurology Podcast Committee.Dr. Salloway serves on scientific advisory boards for Myriad Genetics, Inc, Elan Corporation, Sanofi-aventis, Eisai Inc., and Pfizer; serves on the editorial board of the Journal of Neuropsychiatry and Clinical Neurosciences; receives royalties from American Psychiatric Press Inc and Humana Press; received speaker honoraria from Eisai Inc., Pfizer, Novartis, Forest Laboratories, Inc. and Elan Corporation; serves as a consultant to Merck Serono and Medivation-data safety committee; receives research support from Elan Corporation, Wyeth, Bristol-Myers Squibb, Alzheimers Disease Neuroimaging Initiative, Dominantly Inherited Alzheimers Network, Aging Brain: DTI, Subcortical Ischemia and Behavior and NIH [NIA 1 R03 AGO23916-01A1]; receives funding from The Norman and Rosalie Fain Family Foundation.

This Podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Sam Taylor interview Dr. Una McCann about her paper on recreational MDMA (Ecstasy). In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week about EEG for diagnosis of tick paralysis. The podcast concludes where Dr. Ted Burns provides an introduction to Dr. Mateens interview with Dr. Donald Mulder which was recorded for the January 8, 2008 Lesson of the Week. Dr. Mulders In Memoriam is published in this issue. The participants had nothing to disclose except Dr. McCann. Dr. McCann has served on a scientific advisory board and speakers bureau for Jazz Pharmaceuticals; has received honoraria from Public Health Service and the Veterans Administration (grant reviews); and receives research support from the NIH [NIDA #R01 DA010217 (PI), NHLBI/NIDA #1 R01 Hl071501 (PI), NIDA # 1RO1 DA017231-01 A1 (Co-I), NIDA #2 RO1 DA05707 (Co-I), NIDA #2 RO1 DA05938 (Co-I), and NICHHD #1 R01 HD050202-01 (Co-I).]

This Podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Mark Keegan interview Dr. Massimo Filippi about his paper on oral vs. intravenous methyprednisolone in MS. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week about pseudo-myasthenic ptosis. The next part of the podcast is Dr. Alberto Espay interviews Dr. Josep Dalmau for our Lesson of the week toolbox about NMDAR encephalitis. The participants had nothing to disclosure except Drs. Keegan, Filippi, Espay and Dalmau. Dr. Keegan serves as Section Co-Editor for Neurology and the Neurology Podcast Panel.Dr. Filippi serves on scientific advisory boards for Teva Pharmaceutical Industries Ltd. and Genmab A/S; has received funding for travel from Bayer Schering Pharma, Biogen-Dompè AG, Genmab A/S, Merck Serono, and Teva Pharmaceutical Industries Ltd.; serves on editorial boards of the American Journal of Neuroradiology, BMC Musculoskeletal Disorders, Clinical Neurology and Neurosurgery, Erciyes Medical Journal, Journal of Neuroimaging, Journal of Neurology Neurosurgery and Psychiatry, Journal of Neurovirology, Magnetic Resonance Imaging, Multiple Sclerosis, and Neurological Sciences ; serves as a consultant to Bayer Schering Pharma, Biogen-Dompè AG, Genmab A/S, Merck Serono, Pepgen Corporation, and Teva Pharmaceutical Industries Ltd.; serves on speakers' bureaus for Bayer Schering Pharma, Biogen-Dompè AG, Genmab A/S, Merck Serono, and Teva Pharmaceutical Industries Ltd.; and receives research support from Bayer Schering Pharma, Biogen-Dompè AG, Genmab A/S, Merck Serono, Teva Pharmaceutical Industries Ltd., Fondazione Italiana Sclerosi Multipla, and Fondazione Mariani. Dr. Espay has received personal compensation as a consultant for Boehringer Ingelheim; grant support from Codman; Medtronic, Inc; Allergan, Inc.; and CleveMed, and honoraria from UCB-SCHWARZ PHARMA AG; Medtronic, Inc. and Novartis.Dr. Dalmau has received honoraria for lectures not funded by industry; receives research support from EUROIMMUN and the NIH/NCI [RO1CA107192 (PI) and RO1CA89054-06A2 (PI)]; has received license fee payments from EUROIMMUN for an NMDA receptor autoantibody test (patent pending PCT/US07/18092, filed: August 15, 2007); and has received royalty payments and may accrue revenue for US Patent 6,387,639;, issued: May 14th, 2002: Patent for Ma2 autoantibody test.

This Podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Heather Harle interview Dr. Rod Adam about his paper on coccidioidal meningitis and brain abscesses. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week about isolated medial rectus palsy in midbrain infarction. The next part of the podcast is Dr. Alberto Espay interviews Dr. Daniel Weintraub for our Lesson of the week toolbox about MoCA vs MMSE. In concluding, there is a brief statement where to find other up-to date patient information and current Patient Page. The participants had nothing to disclosure except Drs. Espay and Weintraub. Dr. Espay has received personal compensation as a consultant for Boehringer Ingelheim; grant support from Codman; Medtronic, Inc; Allergan, Inc.; and CleveMed, and honoraria from UCB-SCHWARZ PHARMA AG; Medtronic, Inc. and Novartis.Dr. Weintraub has served on a scientific advisory board for Boehringer Ingelheim ; serves on the editorial board of Movement Disorders; has received honoraria from Boehringer Ingelheim, ACADIA Pharmaceuticals Inc., Novartis, Osmotica Pharmaceutical Corp., BrainCells Inc., Merck Serono, Sanofi-aventis, and Pfizer Inc; and receives research support from Boehringer Ingelheim and the NIH [#K23 MH067894 (Principal Investigator)].

This Podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Interim Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Michelle Mauermann interview Dr. Hiroshi Mitsumoto about his paper on how progressive muscular atrophy is a form of ALS. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week about neuromuscular disorders unmasked by statin therapy. The podcast concludes where Dr. Beau Bruce interviews Dr. Brian Weinshenker for the Lesson of the Week (disease of the month) on neuromyelitis optica. The participants had nothing to disclose except Drs. Mitsumoto & Weinshenker. Dr. Mitsumoto has served on scientific advisory boards for and/or received speaker honoraria from Avanir Pharmaceuticals, Knopp Neurosciences Inc., Neuralstem, Inc., and Sanofi-aventis, and Otsuka Pharmaceutical Co., Ltd.; and has received research support from Avanir Pharmaceuticals, Teva Pharmaceutical Industries Ltd., Knopp Neurosciences Inc., the NIH [NINDS #R01NS04812 (Co-I) and NIEHS #1R01ES016348-01A2 (PI)], the Muscular Dystrophy Association, the ALS Association, and the MDA Wings Over Wall Street.Dr. Weinshenker serves as an editorial board members for Canadian Journal of Neurosciences and Turkish Journal of Neurology, received revenue for a patent held by Mayo Foundation licensed to RSR Limited, was a consultant for CaridianBCT in 2008, and receives research support from the Guthy-Jackson Charitable Foundation.

This Podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Interim Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Matthew Barrett interview Drs. Pablo Martinez-Martin and K. Ray Chaudhuri about their paper on non-motor symptoms scale in Parkinson disease. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week about varicella zoster virus can mimic Guillain-Barre syndrome. The podcast concludes where Dr. Ted Burns interviews Dr. David Loring for the Lesson of the Week on psychometric properties. The participants had nothing to disclose except Drs. Martinez-Martin and Chaudhuri. Dr. Martinez-Martin served on a scientific advisory board for Novartis; serves on the editorial boards of Neurologia, the Spanish Society of Neurology, Revista de Neurologia, and Societies of Neurology of the Spanish autonomous regions; has received speaker honoraria from Sanofi aventis and Novartis; and receives research support from Novartis and the Carlos III Institute of Health.Dr. Chaudhuri serves on scientific advisory boards for Solvay Pharmaceuticals, Inc., Boehringer Ingelheim, GlaxoSmithKline, Merck Serono, and Teva Pharmaceutical Industries, Ltd.; has received speaker honoraria from the European Federation of Neurological Societies, the Swedish Movement Disorders Society, and LIMPE Italy; and receives research support for a clinical research nurse from UCB.

This Podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Interim Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interview Dr. Aline Bouwes about her paper on mild hypothermia after cardiopulmonary resuscitation. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week about parkinsonism-hyperpyrexia syndrome. The podcast concludes where Dr. Michael Benatar interviews Dr. Mark Conaway for the Lesson of the Week on sensitivity and specificity. The participants had nothing to disclose.

This Podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Interim Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Russ Swerdlow interview Dr. Dan Larriviere about the AAN paper on neuroenhancements. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week about the Serotonin syndrome. The next part of the podcast is Dr. Alberto Espay interviews Dr. Ruth Walker for our Lesson of the week toolbox about chorea-acanthocytosis. In concluding, there is a brief statement where to find other up-to date patient information and current Patient Page. The participants had nothing to disclosure except Drs. Larriviere, Espay and Walker. Dr. Larriviere has received honoraria for serving on the American Association for the Advancement of Science Faculty and has received an unrestricted educational grant from Allergan, Inc.Dr. Espay has received personal compensation as a consultant for Boehringer Ingelheim; grant support from Codman; Medtronic, Inc; Allergan, Inc.; and CleveMed, and honoraria from UCB-SCHWARZ PHARMA AG; Medtronic, Inc. and Novartis.Dr. Walker has received honoraria from the NYU Medical Center, University of Pennsylvania Medical Center and University of Cincinnati for Grand and Movement Disorders Rounds; received personal compensation as a speaker for Intellyst® Medical Communication on Huntington disease and as a consultant for Scientia Advisors; and government support from Department of Veterans Affairs.

This Podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Interim Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Fabi Nahab interview Dr. Mitch Elkind about his paper on The Northern Manhattan Study. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week about don't get caught with a "bovine arch." The podcast concludes where Dr. Jason Mackey interviews Dr. Daniel Claassen for the Lesson of the Week segment about the Resident & Fellow Section paper about orbital bruits. The participants had nothing to disclose except for Drs. Elkind, Claassen and Mackey.Dr. Elkind serves as Resident and Fellow Section Editor for Neurology; serves as a consultant to Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership, GlaxoSmithKline, Jarvik Heart, Tethys Bioscience, Inc., and Daiichi-Sankyo; serves on speakers' bureaus for Boehringer-Ingelheim, Inc., and Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership; and receives research support from diaDexus, Inc., Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership, and from the NIH/NINDS [# K23 NS42912 (PI), # R01 NS050724 (PI),#NS048134 (PI), # P50 NS049060 (Project PI), # R37 NS029993 (Co-PI), and #R01 NS55809 (Co-I)]; and has given expert testimony on behalf of Merck Serono (Vioxx® litigation), Pfizer Inc (Shiley valve and Celebrex®/Bextra® litigation), and Novartis (Zelnorm® and stroke litigation). Dr. Claassen is a recipient of the AAN Clinical Research Training Fellowship.Dr. Mackey is funded by NIH T-32 training grant [NS 047996-04].

This Podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Interim Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interview Drs. Bob Miller and Carlayne Jackson about the two AAN guidelines on care of patients with amyotrophic lateral sclerosis. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week about the smile of Wilson disease. The podcast concludes where Dr. Beau Bruce interviews Dr. Andrew Norden for the Lesson of the Week Drug/Disease segment about VEGF inhibitors. The participants had nothing to disclose except for Drs. Miller and Jackson.Dr. Miller serves on the editorial board of the ALS Journal; received a speaker honorarium from the AANEM; served as a consultant to Celgene, Knopp Neurosciences Inc., Teva Pharmaceutical Industries Ltd., Taiji Biomedical, Inc., Sanofi-aventis, Novartis, and Neuraltus; and receives research support from the NIH [#R01 NS 44887 (PI)] and the Muscular Dystrophy Association (PI).Dr. Jackson serves as a consultant to Knopp Neurosciences Inc.; and receives research support from Knopp Neurosciences Inc., Insmed Inc., Solstice Neurosciences, Inc., the ALS Association, and from the NIH NINDS [#U01 NS042685-0 (Site PI), # R01NS045087-01A2 (Site PI), and # N01-AR-2250 (Site PI)].

This Podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Interim Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Matthew Barrett interview Dr. Ergun Uc about his paper driving with Parkinson disease. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week about cervical MRI with anterior flexion in Hirayama disease. The podcast concludes where Dr. Casey Hall interviews Dr. Mark Conaway for the Lesson of the Week on Wilcoxon tests. The participants had nothing to disclose except for Dr. Uc.Dr. Uc received an honorarium from Current Medicine Group LLC for writing an invited article; serves on the NIH/NINDS VA Merit Review Board; and receives research support from the Parkinson disease Foundation (PI).

This Podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Interim Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Andy Southerland interview Dr. Pooja Khatri about her paper on outcome after ischemic stroke. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week about neuroimaging in posterior reversible encephalopathy syndrome. The next part of the podcast is Dr. Ted Burns interviews Dr. Nizar Souayah for our LOTW about swine flu and the risk of GBS. In concluding, there is a brief statement where to find other up-to date patient information and current Patient Page. The participants had nothing to disclosure except Dr. Khatri. Dr. Khatri receives royalties from publishing The Stroke Center Handbook (Taylor & Francis Group, 2006-2008); research support from the NIH/NINDS NS059843; and received an honorarium for contributing to Continuum.

This 100th Podcast for the Neurology Journal begins and closes with Dr. Robert Gross, Interim Editor-in-Chief, briefly discussing highlighted articles from the print issue of Neurology. In the second segment Dr. Ted Burns interview Dr. David Beversdorf with Dr. Michael Conn about his book co-authored with Dr. James Parker published in 2008 on research on animals. In the next segment, Dr. Ryan Overman is reading our e-Pearl of the week about Neuroimaging in acute thrombotic thrombocytopenic purpura. The next part of the podcast is Dr. Beau Bruce interviews Dr. Jim Lah for our LOTW about mild cognitive impairment. The participants had nothing to disclosure except Dr. Beversdorf. Dr. Beversdorf has spoken for Pfizer and Novartis until 2008, not related to this work, and has received recent funding from the National Alliance for Autism Research (now Autism Speaks) and NIH for his work.